Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jun 28:2022:2172980.
doi: 10.1155/2022/2172980. eCollection 2022.

Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis

Teng Zhu  1 , Lin Ma  1
Affiliations
Meta-Analysis

Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis

Teng Zhu et al. Contrast Media Mol Imaging. .

Abstract

In this study, our purpose was to systematically evaluate the efficacy and safety of interleukin-23 (IL-23)-targeted drugs in the treatment of moderate-to-severe psoriasis and provide an evidence-based reference for clinical treatment. A computer search of PubMed, EMBASE, Web of Science, Cochrane Library, Chinese Journal Full Text Database, Chinese Science and Technology Journal Database, and Wanfang Database was conducted from the establishment of the database to 2021-09-30. The efficacy of IL-23-targeted drugs (trial group) was compared with placebo (control group) in the treatment of psoriasis; i.e., PASI score improvement of 75% or more (PASI 75, PASI 90, and PASI 100) and the safety of randomized controlled trials (RCTs) were collected. Meta-analysis was performed using Rev Man 5.4.3 statistical software after data extraction for clinical studies that met the inclusion criteria. A total of 9 studies were included, all included studies were large multicenter, randomized, double-blind, placebo-controlled studies, and all used correct randomization methods and were of good quality. Meta-analysis showed that the improvement rates of PASI 75, PASI 90, and PASI 100 in the test group were superior to those in the control group (OR = 70.21 (42.25, 166.66), P < 0.00001), (OR = 78.41 (53.09, 115.79), P < 0.00001), and (OR = 77.10 (38.61, 153.99), P < 0.00001), P < 0.05. However, more adverse effects occurred, and the differences were statistically significant. IL-23-targeted drugs have significantly higher response rates compared to placebo in the treatment of psoriasis, and the safety was acceptable.

PubMed Disclaimer

Conflict of interest statement

The authors declared that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Literature screening flow chart.
Figure 2
Figure 2
Methodological quality assessment of included literature trials.
Figure 3
Figure 3
Forest plot for PASI 75.
Figure 4
Figure 4
Forest plot for PASI 90.
Figure 5
Figure 5
Forest plot for PASI 100.
Figure 6
Figure 6
Adverse reactions.
Figure 7
Figure 7
Funnel plot.
See this image and copyright information in PMC

References

    1. Gottlieb A., Korman N. J., Gordon K. B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology . 2008;58(5):851–864. doi: 10.1016/j.jaad.2008.02.040. - DOI - PubMed
    1. Peng C., Xu X., Chen W., et al. Epidemiological Variations in the Global Burden of Psoriasis, an Analysis With Trends from 1990 to 2017. Frontiers of Medicine . 2021;8 doi: 10.3389/fmed.2021.585634.585634 - DOI - PMC - PubMed
    1. Parisi R., Symmons D. P. M., Griffiths C. E. M., Ashcroft D. M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology . 2013;133(2):377–385. doi: 10.1038/jid.2012.339. - DOI - PubMed
    1. Takeshita J., Grewal S., Langan S. M., et al. Psoriasis and comorbid diseases. Journal of the American Academy of Dermatology . 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064. - DOI - PMC - PubMed
    1. Basra M. K., Shahrukh M. Burden of skin diseases. Expert Review of Pharmacoeconomics & Outcomes Research . 2009;9(3):271–283. doi: 10.1586/erp.09.23. - DOI - PubMed

Publication types